Skip to Content

Naglazyme BioMarin Pharmaceutical Inc. - Treatment for Mucopolysaccharidosis VI (MPS VI)

Naglazyme (formerly rhASB) is an enzyme-replacement therapy for treatment of mucopolysaccharidosis VI (MPS VI), an inherited, life-threatening lysosomal storage disorder caused by a deficiency of the lysosomal enzyme N-acetylgalactosamine 4-sulfatase (also known as arylsulfatase B).

Posted: May 2005

Related Articles:

Naglazyme (galsulfase) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.